ID   NSCLC-N6
AC   CVCL_H623
SY   NSCLCN6
DR   ChEMBL-Cells; CHEMBL3307850
DR   ChEMBL-Targets; CHEMBL614016
DR   PubChem_Cell_line; CVCL_H623
DR   Wikidata; Q54931063
RX   PubMed=1776865;
RX   PubMed=9568077;
CC   Doubling time: ~48 hours (PubMed=1776865).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 12
CH   CVCL_H624 ! NSCLC-N6 clone C15
CH   CVCL_H625 ! NSCLC-N6 clone C65
CH   CVCL_H626 ! NSCLC-N6 clone C92
CH   CVCL_H627 ! NSCLC-N6 clone C98
//
RX   PubMed=1776865;
RA   Roussakis, Christos
RA   Gratas, Catherine
RA   Audouin, Anne-Francoise
RA   Le Boterff, Jean
RA   Dabouis, Gerard
RA   Andre, Marie-Josephe
RA   Moyon, E.
RA   Vo, Ngoc Huong
RA   Pradal, Gilbert
RA   Verbist, Jean-Francois
RT   "Study of in vitro drug sensitivity on a newly established cell line
RT   from a primary bronchial epidermoid carcinoma of human origin
RT   (NSCLCN6).";
RL   Anticancer Res. 11:2239-2244(1991).
//
RX   PubMed=9568077;
RA   Siavoshian, Samila
RA   Boesch, Steffi
RA   Pondaven, Per
RA   More, Marie-Therese
RA   Riou, Denis
RA   Dabouis, Gerard
RA   Andre, Marie-Josephe
RA   Roussakis, Christos
RT   "Cloning of a human cancer cell line (NSCLC-N6) and comparative study
RT   of the clones in vitro.";
RL   Anticancer Res. 18:193-200(1998).
//